Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma Allogeneic hematopoietic stem cell ...
Recently published Hematopoietic Stem Cell Transplantation Market Insights report includes a comprehensive understanding of current treatment practices, hematopoietic stem cell transplantation ...
Most inborn errors of immunity (IEIs) are caused by defects that arise somewhere along the developmental path between hematopoietic stem cells (HSCs) and mature immune cells. Replacement of mutant ...
Hematopoietic stem cell transplantation (HSCT) use in CLL decreased by 42% from 2009 to 2018 due to new treatment options. Non-relapse mortality (NRM) improved significantly, attributed to enhanced ...
Allogeneic HSCT achieved 92% sustained, medication-free remission and 100% survival in children with monogenic IBD, highlighting its potential as a transformative treatment. Monogenic IBD, ...
1.5-year clinical outcomes in patients with triple-mutated AML who were positive and negative for MRD before allo-HSCT. This paper explores the clinical outcomes of allogeneic hematopoietic stem cell ...
Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients. While the procedure offers hope for many, infections remain ...
A collaborative team of researchers from Children's Hospital of Philadelphia (CHOP) found that hematopoietic stem cell transplantation (HSCT) is a highly effective method for treating patients with ...
Novel allogeneic T-cell-based immunotherapy reduces chronic graft-versus-host disease (GVHD) in patients with blood cancers ...
The hematopoietic stem cell transplantation market is experiencing steady growth, driven by the rising prevalence of hematologic malignancies, advances in transplant techniques, donor matching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results